Helen C. Adams - 22 May 2026 Form 4 Insider Report for Immix Biopharma, Inc. (IMMX)

Reporting relationship: Director
Issuer ticker: IMMX
Reported as of: 22 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 17:05:26 UTC
Prior SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Ilya Rachman as Attorney-In-Fact for Helen C. Adams

Key filing fact

Helen C. Adams filed Form 4 for Immix Biopharma, Inc. (IMMX) on 29 May 2026.

Key facts

This page summarizes Helen C. Adams's Form 4 filing for Immix Biopharma, Inc. (IMMX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 May 2026, 17:05.

Change

Previous filing in this sequence was filed on 23 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001488486 Primary reporting owner

Adams Helen C.

Relationship: Director
Address: C/O IMMIX BIOPHARMA, INC., 11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES
Signature: /s/ Ilya Rachman as Attorney-In-Fact for Helen C. Adams
Signature date: 29 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMMX transaction

Common Stock

Award

Transaction value
Shares: +6,250
Change %: +3.6%
Price: $0.000000^*
Shares after: 181,004
Date: 22 May 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMMX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +12,500
Change %
Price: $0.000000^*
Shares after: 12,500
Date: 22 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $8.78
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.

Footnote F2

The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.